Predictive Oncology Inc (US:POAI) — Company Overview, News & Financial Data
Predictive Oncology uses AI to develop personalized cancer therapies, enhancing clinical outcomes and drug discovery.
POAIPredictive Oncology Inc
Company profile
About Predictive Oncology Inc
Predictive Oncology (NASDAQ:POAI) focuses on using artificial intelligence to revolutionize cancer treatment. Traded on the Nasdaq, the company is known for its cutting-edge technology that analyzes vast amounts of data to tailor personalized cancer therapies. Its main operations include drug discovery, data analytics, and precision medicine solutions. One of the flagship projects involves a robust platform that predicts how cancer patients respond to various treatments, thereby improving clinical outcomes. The company’s objectives center on enhancing predictive models and expanding collaborations with research institutions and pharmaceutical companies. By harnessing AI, Predictive Oncology aims to offer groundbreaking solutions that personalize cancer care, ultimately making treatments more effective and accelerating drug development processes.
Snapshot
Public USOwnership
2018Year founded
23Employees
Eagan, United StatesHead office
Loading Map...
Global footprint
Operations
All Locations
United States
Products and/or services of Predictive Oncology Inc
- PeDAL: A platform leveraging AI to identify optimal cancer drug therapies, comparing billions of drug interactions, and presenting comprehensive treatment strategies for personalized medicine.
- Soluble Biologics: A service that enhances protein production and stability through its proprietary technology, optimizing the solubility and efficacy of therapeutic proteins for pharmaceutical applications.
- Helomics: Specializes in leveraging its extensive database of tumor profiles to support the drug discovery process, aiding in the development of individualized cancer treatment plans.
- TumorGenesis: Focuses on creating patient-derived tumor models that mimic the biological environment of specific cancers, providing a more accurate platform for drug testing and development.
- BioDuro LLC Acquisition: As enhances service portfolio through integrated drug formulation and manufacturing capabilities, supporting end-to-end pharmaceutical development with a strong focus on oncology.
- AI-driven Data Analytics: Develops predictive models using machine learning to streamline drug discovery processes, enhancing decision-making by analyzing vast experimental datasets.
Predictive Oncology Inc executive team
- Mr. Raymond F. VennareCEO & Chairman
- Mr. Joshua Blacher CPA, M.B.A.Interim Chief Financial Officer
- Mr. Thomas McLaughlinChief Investment Officer
- Ms. Sara Turken J.D.Senior VP & General Counsel
- Dr. Lawrence J. DeLucas D.Sc, O.D, Ph.D.Senior Vice President of Biologics
- Dr. Arlette H. Uihlein FCAP, M.D.Senior VP of Translational Medicine & Drug Discovery and Medical Director